ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

NEWS & VIEWS

Oxford Capital and our portfolio companies

$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics

By Oxford Capital November 26, 2014
Read More

Veryan's BioMimics 3D Nitinol stent shows improved patency at 2-year follow-up in Mimics randomized controlled study

By Oxford Capital November 6, 2014
Read More

Outplay announces Monster Legacy has been nominated for Scottish BAFTA

By Oxford Capital October 23, 2014
Read More

Oxford Capital To Attend Major Infrastructure Investment Conference

By Oxford Capital October 3, 2014
Our investor relations team, who look after our growing base of institutional clients, are delighted to be involved with the AltAssets LP-GP Infrastructure Conference. At the event, which takes place in London on 7th October, we will be hosting a panel discussion entitled, “Filling the Vacuum: The emergence of new Infrastructure”. We will explore how…
Read More

Oxford BioTherapeutics Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

By Oxford Capital October 2, 2014
Read More

MirriAd announces partnership with Universal Music Group and Havas

By Oxford Capital September 29, 2014
Read More

Will you love your Apple Watch, or keep it in a drawer?

By Oxford Capital September 26, 2014
The noise surrounding ‘wearable technology’ has built to a crescendo with the announcement of the Apple Watch, due to hit the shelves in early 2015. But will this be the moment that wearable technology finally hits the mainstream, or will most consumers decide they just don’t need any more gadgets in their lives? The market…
Read More

Oxitec Exit To Be Showcased At Major Venture Capital Event

By Oxford Capital September 24, 2014
Ted Mott, Managing Partner of Oxford Capital, and Hadyn Parry, CEO of Oxitec, have been invited to take part in a panel discussion at the British Venture Capital Association’s annual summit on 8th October. Oxitec was recently acquired by US biotech business Intrexon Corporation, in a deal which valued Oxitec at up to $160m. Oxford…
Read More

Biomonde fundraising round wins Insider Media's Dealmaker Award

By Oxford Capital September 22, 2014
Read More

Schurz communications and iJento to combine online and offline subscriber knowledge

By Oxford Capital September 9, 2014
Read More

Awards

  • BEST EIS
    FUND MANAGER
    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR
    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR
    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT
    WINNER 2017

  • BEST ANGEL
    SYNDICATE
    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY
    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS
    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH
    2020